MedTrace Logo

Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)

NCT01929616 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2019-06-25

No results posted yet for this study

Summary

The general objectives are to evaluate activity and the safety of regorafenib in a population of patients bearing advanced, refractory colorectal cancers and to explore the different downstream molecular pathways to identify tumor response and resistance mechanisms.

Conditions

  • Advanced Chemorefractory Colorectal Adenocarcinoma

Interventions

DRUG

regorafenib

Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Alain Hendlisz, MD · Jules Bordet Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-05-13
Completion
2019-06-17

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01929616 on ClinicalTrials.gov